Evidence map›Paper›PMID 37750932›Full record

ArticleCancer chemotherapy and pharmacology2024

Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma.

Hajime Yasuda, Naoko Kaga, Hikari Taka, Tomonori Ochiai, Tomohito Yamana, Yoshiki Miura, Midori Ishii, Makoto Sasaki, Jun Ando, Miki Ando

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hajime YasudaDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongou, Bunkyo-Ku, Tokyo, 113-8421, Japan. hyasuda@juntendo.ac.jp.ORCID 0000-0002-2896-7737
Naoko KagaLaboratory of Proteomics and Biomolecular Science, Biomedical Research Core Facilities, Juntendo University Graduate School of Medicine, Bunkyo-Ku, Tokyo, Japan.
Hikari TakaLaboratory of Proteomics and Biomolecular Science, Biomedical Research Core Facilities, Juntendo University Graduate School of Medicine, Bunkyo-Ku, Tokyo, Japan.
Tomonori OchiaiDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongou, Bunkyo-Ku, Tokyo, 113-8421, Japan.
Tomohito YamanaDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongou, Bunkyo-Ku, Tokyo, 113-8421, Japan.
Yoshiki MiuraLaboratory of Proteomics and Biomolecular Science, Biomedical Research Core Facilities, Juntendo University Graduate School of Medicine, Bunkyo-Ku, Tokyo, Japan.
Midori IshiiDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongou, Bunkyo-Ku, Tokyo, 113-8421, Japan.
Makoto SasakiDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongou, Bunkyo-Ku, Tokyo, 113-8421, Japan.
Jun AndoDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongou, Bunkyo-Ku, Tokyo, 113-8421, Japan.
Miki AndoDepartment of Hematology, Juntendo University School of Medicine, 2-1-1 Hongou, Bunkyo-Ku, Tokyo, 113-8421, Japan.
Juntendo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeChemotherapy for the hemodialysis (HD) patient is a challenging situation because it requires special considerations including dose modifications and timing of drug administration in relation with HD sessions. Polaltuzumab vedotin (PV), an antibody-drug conjugate in which monomethyl auristatin E (MMAE) is linked to an anti-CD79b monoclonal antibody, is an extremely promising therapeutic for treating diffuse large B cell lymphoma (DLBCL), but the pharmacokinetics are unknown in HD patients.

methodsWe carried out pharmacokinetic studies of PV when administered at 1.2 mg/kg to a DLBCL patient on HD, and compared the results with that of non-HD patients. PV was administered in conjunction with bendamustine and rituximab.

resultsSerum concentration-time curves of both antibodyconjugated and unconjugated MMAE in the presented HD patient were similar compared to that of non-HD patients. We also demonstrate that elimination of both antibody-conjugated and unconjugated MMAE through HD is limited. PV administration at 1.2 mg/kg to an HD patient was also clinically feasible, and no signs of peripheral neuropathy were observed.

conclusionsPV therapy may be a relatively safe treatment method for DLBCL patients on HD.

Indexed as

ImmunoconjugatesLymphoma, Large B-Cell, DiffuseAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsHumansRituximabAntibodies, MonoclonalImmunoconjugatespolatuzumab vedotinRituximabBendamustineBrentuximab vedotinMMAE (monomethyl auristatin E)Pola-BR (polatuzumab vedotinPolivyRenal replacement therapyRituximab)

Identifiers

PMID37750932
OpenAlexW4387032941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.